RD-23

• Description :

  RD-23 is an orally active and selective RET PROTAC degrader. RD-23 promotes ubiquitination and degradation of RETG810C mutation, with a DC50 value of 11.7 nM. RD-23 inhibits the activation of downstream Shc signaling and induces Apoptosis. RD-23 can be used for the research of RET-related cancers (Pink: RET ligand-2 (HY-168868) ; Blue: E3 ligase CRBN ligand; Black: linker) [1].

• UNSPSC :

  12352005

• Target :

  Apoptosis; PROTACs; RET

• Related Pathways :

  Apoptosis; PROTAC; Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Smiles :

  N#CC1=C2C(C3=CC=C(N=C3)N4CC5CC(C4)N5CC6=CC=C(N=C6)OC)=CC(N7CCC(CC7)N8CCN(CC8)CCCC#CC9=CC=CC%10=C9CN(C%10=O)C(C(N%11)=O)CCC%11=O)=CN2N=C1

• Molecular Formula :

  C52H56N12O4

• Molecular Weight :

  913.08

• References & Citations :

  [1]Hualong M, et al. Discovery of a Selective and Orally Bioavailable RET Degrader with Effectiveness in Various Mutations. J Med Chem. 2025 Jan 7.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [3053537-06-4]